Insider Selling: Aveanna Healthcare (NASDAQ:AVAH) Insider Sells $97,693.25 in Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Patrick Cunningham sold 12,445 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $7.85, for a total transaction of $97,693.25. Following the transaction, the insider owned 293,354 shares of the company’s stock, valued at $2,302,828.90. The trade was a 4.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Aveanna Healthcare Stock Down 1.1%

Shares of AVAH stock opened at $8.08 on Monday. The firm’s fifty day moving average price is $8.92 and its two-hundred day moving average price is $7.52. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 140.39. Aveanna Healthcare Holdings Inc. has a 1 year low of $3.67 and a 1 year high of $10.32. The firm has a market capitalization of $1.69 billion, a P/E ratio of 22.44 and a beta of 2.06.

Aveanna Healthcare (NASDAQ:AVAH) last announced its quarterly earnings data on Monday, May 22nd. The company reported $0.04 earnings per share for the quarter. The company had revenue of $450.53 million during the quarter. Aveanna Healthcare had a negative return on equity of 143.55% and a net margin of 3.29%. On average, equities analysts predict that Aveanna Healthcare Holdings Inc. will post -0.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on AVAH. Truist Financial increased their price objective on Aveanna Healthcare from $9.50 to $10.00 and gave the company a “hold” rating in a report on Friday, November 7th. Royal Bank Of Canada increased their price target on shares of Aveanna Healthcare from $8.00 to $10.00 and gave the company a “sector perform” rating in a research note on Friday, October 24th. Weiss Ratings reissued a “hold (c+)” rating on shares of Aveanna Healthcare in a research report on Monday, December 29th. BMO Capital Markets assumed coverage on shares of Aveanna Healthcare in a report on Thursday, November 13th. They issued an “outperform” rating and a $11.00 target price on the stock. Finally, UBS Group lifted their price target on Aveanna Healthcare from $9.00 to $9.50 and gave the stock a “neutral” rating in a report on Friday, November 7th. Five research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $10.69.

Aveanna Healthcare News Roundup

Here are the key news stories impacting Aveanna Healthcare this week:

• Negative Sentiment: CEO Jeff Shaner sold multiple blocks (roughly 83,000+ shares across Dec. 30–Jan. 2 in the filings), at prices around $8.18–$8.36, reducing his stake by about 1–1.2% in individual trades while retaining a multi‑million‑share holding — investors may view repeated CEO sales as a negative signal. SEC filing — Jeff Shaner
• Negative Sentiment: CFO Matthew Buckhalter executed several sales (totaling ~70,000+ shares across Dec. 30–Jan. 2) at roughly $7.85–$8.36, each reducing his position by ~3.5–4%. Repeated CFO sales can raise governance/comfort concerns for short‑term holders. SEC filing — Matthew Buckhalter
• Negative Sentiment: CAO Deborah Stewart sold multiple blocks (~34,000+ shares across Dec. 30–Jan. 2) at similar price levels, trimming her stake by ~4% in reported trades while keeping a substantial holding — another senior exec sale that may pressure sentiment. SEC filing — Deborah Stewart
• Negative Sentiment: Insider Edwin C. Reisz sold multiple tranches (~51,000+ shares across Dec. 30–Jan. 2) at $7.85–$8.36, reducing his position by ~1.2% in several filings. Multiple insider sellers across ranks amplify negative interpretation. SEC filing — Edwin C. Reisz
• Negative Sentiment: Insider Patrick A. Cunningham reported several sales (~36,000+ shares across Dec. 30–Jan. 2) at similar price points, lowering his stake by ~3.6–4.1% in the disclosed trades. Collective insider selling increases perceived supply risk. SEC filing — Patrick A. Cunningham

Hedge Funds Weigh In On Aveanna Healthcare

Several large investors have recently modified their holdings of AVAH. Banque Transatlantique SA acquired a new stake in shares of Aveanna Healthcare during the 1st quarter worth about $25,000. Quantbot Technologies LP bought a new position in Aveanna Healthcare in the 2nd quarter valued at about $43,000. Diversified Trust Co acquired a new stake in Aveanna Healthcare during the second quarter worth approximately $57,000. Jump Financial LLC bought a new stake in shares of Aveanna Healthcare during the first quarter worth approximately $59,000. Finally, MQS Management LLC acquired a new position in shares of Aveanna Healthcare in the second quarter valued at approximately $59,000. 87.96% of the stock is owned by institutional investors.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.